Want to see HK:2186 full AI Analyst Report?
2186 Stock Chart & Stats
HK$3.02
HK$0.04(1.95%)
At close: 4:00 PM EST
HK$3.02
HK$0.04(1.95%)
Day’s Range― - ―
52-Week RangeHK$1.73 - HK$4.49
Previous CloseN/A
Volume7.60M
Average Volume (3M)38.67M
Market Cap
HK$7.98B
Enterprise ValueHK$11.71B
Total Cash (Recent Filing)HK$8.88B
Total Debt (Recent Filing)HK$9.42B
Price to Earnings (P/E)10.1
Beta0.91
Next Earnings
Aug 27, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,994,515,900
10 Day Avg. Volume34,399,920
30 Day Avg. Volume38,673,367
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.60
Price to Sales (P/S)1.52
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.22Price Target Upside39.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$6.95B
Bulls Say, Bears Say
Bulls Say
High MarginsConsistently high gross (~66%) and strong EBIT/EBITDA margins indicate durable pricing power and efficient manufacturing for branded medicines. Such margin strength supports sustained reinvestment into R&D and commercialization, helps absorb demand shocks, and underpins longer-term cash-generation capacity.
Improved LeverageDebt-to-equity reduction to ~0.59 materially improves financial flexibility and lowers interest burden, increasing capacity to fund targeted M&A or pipeline investment. Improved leverage also raises resilience to cyclical revenue dips and strengthens the company’s ability to execute longer-term strategic initiatives.
Diversified Product & Channel MixA multi-therapeutic portfolio and mixed commercialization model (self-operated plus partner-supported) diversifies revenue sources and reduces single-product dependency. This structural diversity supports steadier medium-term revenue as different franchises and partner deals mature and cross-market opportunities are exploited.
Bears Say
Steep Revenue DropA ~37% revenue contraction in 2025 is a material structural concern: it can erode scale economics, reduce absolute profitability, and indicate lost market share or product lifecycle issues. Restoring durable growth will require successful launches, regained commercial traction, or meaningful new partnerships.
Volatile Free Cash FlowMulti-year volatility in free cash flow, despite a 2025 rebound, weakens confidence in consistent internal funding for R&D, dividends, or acquisitions. Irregular cash conversion increases reliance on external financing at inopportune times and raises risk for sustained investment in pipeline and commercialization.
Low Return On EquityROE around 3.7% suggests the expanded equity base and assets are not translating into strong shareholder returns. Persistently low ROE signals potential inefficiencies in capital allocation or below-par net-margin conversion, which can constrain long-term investor confidence and limit the payoff from asset growth.
Luye Pharma Group News
2186 FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was HK$1.73 and its highest was HK$4.49 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Luye Pharma Group Ltd.’s market cap is HK$7.98B.
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 51 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Mar 30, 2026. The company reported HK$0.092 earnings per share for the quarter, the consensus estimate of HK$0.092 by HK$0.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Undervalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. pays a Annually dividend of HK$0.06 which represents an annual dividend yield of N/A. See more information on Luye Pharma Group Ltd. dividends here
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate is 0.06.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,994,515,900 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of HK$0.092 in its last earnings report, expectations of HK$0.092. Following the earnings report the stock price went up 3.719%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in HK:2186
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Luye Pharma Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.45%
12-Months-Change
Fundamentals
Return on Equity
4.02%
Trailing 12-Months
Asset Growth
15.79%
Trailing 12-Months
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments: Lipusu for ovarian and breast cancers; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injectable medication for various cancers and solid tumors. It also offers Yitaida for acute promyelocytic leukemia and liver cancer, and Lutingnuo, a glutathione injection for combating toxicity and injuries from ionizing radiation. Tiandixin serves as an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections. In the metabolic and cardiovascular health sector, Luye Pharma provides Xuezhikang, a lipid-regulating drug for hypercholesterolemia; Beitangning, a pioglitazone hydrochloride capsule for blood glucose control; and Beixi, an acarbose capsule for Type 2 diabetes. For neurological conditions and pain management, offerings include Maitongna, indicated for cerebral edema caused by trauma or surgery, and for venous reflux disorders. Transdermal patches such as Rivastigmine are available for Alzheimer's disease, Fentanyl for cancer pain, and Buprenorphine for chronic pain relief. Additionally, Seroquel and Seroquel XR are provided for treating schizophrenia and manic episodes associated with bipolar affective disorders. Rykindo, an injection for schizophrenia, is also part of their neurological therapeutics. Further therapeutic solutions span various conditions: Nuosen for acute upper digestive tract hemorrhage; Sailimai for diarrhea treatment; and the Apleek Transdermal Patch for contraception. Addressing musculoskeletal and inflammatory issues, the company offers Sidinuo for osteoporosis, Glucosamine hydrochloride tablets for osteoarthritis, Oulai (a compound sodium aescinate gel) for localized swelling, Oukai for soft tissue swelling and venous edema, and Fengshiye for pain in bones, joints, and limbs. Beyond product development, Luye Pharma Group actively engages in the distribution and commercialization of its pharmaceutical drugs, along with the manufacturing and sale of biopharmaceutical products. The company was established in 1994 and is headquartered in Yantai, People's Republic of China.
2186 Stock 12 Month Forecast
Average Price Target
HK$4.22
▲(39.74% Upside)
Technical Analysis
CSPC Pharmaceutical Group
―
Zai Lab Ltd
―
Consun Pharmaceutical Group Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Options Prices
Currently, No data available
---